Tagrisso, Imfinzi, Truqap, and Enhertu all reported double-digit sales growth during the fourth quarter and full-year 2025 ...
The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...
NEW YORK – Yatiri Bio's artificial intelligence-based proteomic platform is giving new hope to a SMARCA2/4 inhibitor program that Foghorn Therapeutics previously halted. After seeing Yatiri's ability ...
The FDA raised concerns about multiple facets of the study protocol used to evaluate RGX-121, including the eligibility criteria and surrogate endpoints.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results